Avita Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCEL research report →
Range $11 – $20
Price Chart
About the company
AVITA Medical, Inc. , together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
- CEO
- Cary G. Vance
- IPO
- 2012
- Employees
- 226
- HQ
- Valencia, CA, US
Get TickerSpark's AI analysis on RCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $388.05M
- P/E
- -13.13
- Fwd P/E
- 1679.57
- PEG
- -0.29
- P/S
- 4.58
- P/B
- -15.53
- EV/EBITDA
- -14.89
- Div Yield
- 0.00%
- Gross Margin
- 82.36%
- Op Margin
- -33.89%
- Net Margin
- -42.65%
- ROE
- 146.38%
- ROIC
- -120.79%
Latest fiscal year · YoY change
- Revenue
- $71.61M+11.5%
- Gross Profit
- $58.82M+6.6%
- Op Income
- $-42,534,000
- Net Income
- $-48,587,000+21.4%
- EPS
- $-1.74+27.2%
- OCF Growth
- +36.3%
- FCF Growth
- +43.5%
- 52W High
- $18.43
- 52W Low
- $3.22
- 50D MA
- $13.96
- 200D MA
- $7.45
- Beta
- 2.01
- RSI (14)
- 51
- Avg Volume
- 417.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AVITA delivered strong Q3 revenue growth, improved gross margin and sharply lower cash use, then raised full-year guidance and reiterated a Q4 cash flow breakeven लक्ष्य.· November 5, 2026
- Revenue was $26.1 million, up 53% year over year and 20% sequentially, driven by RECELL and Cohealyx.
- Gross margin improved to 84% from 81.3% a year ago and 81.9% in Q2.
- Cash use fell to about $600,000 from $3.2 million in Q2, and management said cash flow breakeven remains on track for Q4.
- Full-year revenue guidance was raised to $92 million-$94 million from $86 million-$89 million, the second consecutive quarterly increase.
- The company said it also received the remaining $10 million from its Perceptive credit facility after hitting the revenue milestone.
Third-quarter revenue was $26.1 million, up 53% from $17.1 million in the prior-year quarter and up 20% from Q2. Gross margin was 84%, compared with 81.3% last year and 81.9% in Q2, and gross profit was approximately $21.9 million, up about $4.2 million sequentially. Net loss improved to $6.2 million, or $0.20 per share, versus $13.2 million, or $0.46 per share, a year ago. Net cash use declined to approximately $600,000 from $3.2 million in Q2 and $9.9 million in Q1, and the company ended September with about $10.5 million in cash equivalents and marketable securities. Management raised full-year 2026 revenue guidance to $92 million-$94 million from $86 million-$89 million and reiterated expectations for cash flow breakeven in Q4.
Cary Vance framed the quarter as proof that AVITA’s strategy is working: recapturing RECELL utilization, broadening physician use, and adding adoption for Cohealyx and PermeaDerm. He emphasized a focused commercial model aimed at high-volume burn and Level I trauma centers, and said the company is seeing broader use within accounts rather than relying on a single growth driver. His tone was notably confident and methodical, but he also acknowledged some Q3 benefit from seasonality and said the team is still learning the pattern.
David O’Toole highlighted operating leverage: revenue rose 20% sequentially while operating expenses were flat at $24.6 million, helping gross margin rise to 84%. He said RECELL gross margin was 88.4% and expects it to remain between 85% and 90% over the coming quarters, while noting Cohealyx and PermeaDerm carry lower margins. He also pointed to improved liquidity, saying the company received the remaining $10 million from the Perceptive facility after meeting the $85 million trailing-12-month revenue milestone, and that management and the auditor concluded substantial doubt about going concern had been alleviated.
Analysts focused on whether Q3 included meaningful seasonality pull-forward and how to think about 2027 growth. Cary estimated the Q3 seasonal lift at about $1 million and said the core growth trend remains intact, with Q4 guidance reflecting a straight-line continuation of the underlying trajectory. On operating expenses, David said headcount should not rise significantly in 2027 and the company intends to keep operating costs around current levels, with only commission variability tied to revenue growth.
The bull case is that AVITA is showing sustained commercial momentum across the portfolio, not just one product: RECELL grew 20% sequentially, Cohealyx continued to add customers, and PermeaDerm has new clinical data to support broader adoption. The company also materially improved cash use, expanded margins, and removed going-concern doubt, which suggests the business is moving toward self-funding operations.
The biggest risks raised on the call are that some of the Q3 strength may have been helped by summer seasonality, which management estimated at about $1 million, and that the company is still early in scaling Cohealyx and PermeaDerm. Management also acknowledged that lower-margin products could eventually pressure overall gross margin as they grow, and 2027 operating expense discipline will depend on keeping headcount and spending tightly controlled while commissions rise with sales.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.2%
- Shares Outstanding
- 24.84M
- Float Shares
- 23.89M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.44M | ▲ 79.10K |
| Vanguard Capital Management LLC | 1.34M | ▲ 7.62K |
| Marshall Wace, Llp | 700.75K | ▲ 362.36K |
| Blackrock, Inc. | 559.52K | ▼ 5.43K |
| Geode Capital Management, LLC | 337.84K | ▼ 1.98K |
| Aqr Capital Management LLC | 321.01K | ▲ 226.65K |
| Walleye Capital LLC | 263.56K | ▲ 263.56K |
| Squarepoint Ops LLC | 253.22K | ▲ 230.21K |
| Qube Research & Technologies Ltd | 243.39K | ▲ 179.61K |
| Bnp Paribas Financial Markets | 231.77K | ▲ 177.81K |
| Arrowstreet Capital, Limited Partnership | 201.13K | ▲ 140.39K |
| Vanguard Fiduciary Trust Co | 188.57K | ▲ 6.17K |
Held by 31 ETFs
Biggest fund positions in RCEL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | O'Toole David D | buy | 2,000 |
| Jun 12, 26 | O'Toole David D | other | 2,000 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,200 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 9, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 3, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jun 3, 26 | Woody Joseph Fralin | buy | 5,000 |
| Jan 20, 26 | McNamara Robert | other | 22,214 |
| Jan 20, 26 | McNamara Robert | other | 16,133 |
| Jan 20, 26 | Woody Joseph Fralin | other | 22,214 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RCEL coverage
Recent articles, reports, and earnings notes.
No research on RCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCEL report →AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes
globenewswire.com · Nov 16
AVITA Medical Shares Rose 329% In A Year, Medicare Resets Its Billing Codes Next
seekingalpha.com · Nov 14
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 11
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 11
AVITA Medical, Inc. (RCEL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
AVITA Medical to Host Investor Webinar Briefing
globenewswire.com · Nov 8
Avita Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 6
AVITA Medical Reports Third Quarter Results
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.